Nelson Dusetti
Jun 21, 2025, 08:57
Nelson Dusetti: Predicting, Understanding, and Better Treating Pancreatic Cancer
Nelson Dusetti, Head of the Translational Research and Innovative Therapies Department at the Cancer Research Centre of Marseille (CRCM), shared a post on LinkedIn:
“Predicting, understanding, and better treating pancreatic cancer
Thank you to La Marseillaise for this report on our research and recent advances in the treatment of resistant tumors, especially pancreatic cancer.
With Raphaël Rodriguez’s team (Institut Curie), we contributed to a study published in Nature on an innovative molecule, fentomycin-1, capable of targeting the most aggressive cancer cells by exploiting their abnormal accumulation of iron to induce their death by ferroptosis.
At CRCM – Cancer Research Center of Marseille, our work focuses on the characterization of resistant cells in pancreatic cancer, those cells that resist treatments, adapt and promote relapse. Thanks to the PaCaOmics program, which we are conducting at the Paoli-Calmettes Institute, we have developed a tool to predict the sensitivity of tumors to chemotherapy (Pancreas-View). The striking result: 27% of patients do not respond to any standard treatment. With our team, we remain mobilized to provide solutions to patients for whom the therapeutic options are still too limited.
Pancreatic cancer continues to progress, especially in the youngest, and remains one of the most fearsome. A better understanding of its biology is essential to offer personalized therapies and anticipate relapses.”
Read OncoDaily’s Recent Article: “Pancreatic Cancer Remission Rate: What Patients Should Know in 2025”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 21, 2025, 08:57
Jun 21, 2025, 06:35
Jun 21, 2025, 06:02